Literature DB >> 17244225

Intravitreal bevacizumab for branch retinal vein occlusion.

Ulrich Spandau, Anne Wickenhäuser, Florian Rensch, Jost Jonas.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17244225     DOI: 10.1111/j.1600-0420.2006.00850.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


× No keyword cloud information.
  6 in total

1.  Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion: results from a prospective randomized study.

Authors:  Josep Callizo; Abed Atili; Nina Antonia Striebe; Sebastian Bemme; Nicolas Feltgen; Hans Hoerauf; Thomas Bertelmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-01-04       Impact factor: 3.117

2.  Early Avastin management in acute retinal vein occlusion.

Authors:  Shaaban A Mehany; Khaled M Mourad; Ahmad M Shawkat; Mohammed F Sayed
Journal:  Saudi J Ophthalmol       Date:  2010-04-04

3.  Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema.

Authors:  Rohit Shetty; Sivakami A Pai; Ajoy Vincent; Nitin Shetty; Kannan M Narayana; Babi Sinha; Bhujang K Shetty
Journal:  Doc Ophthalmol       Date:  2007-10-25       Impact factor: 2.379

4.  Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study.

Authors:  Marilita M Moschos; Michael Moschos
Journal:  Doc Ophthalmol       Date:  2008-01-10       Impact factor: 2.379

5.  Erectile dysfunction following intravitreal bevacizumab.

Authors:  Jayshan Yohendran; Devinder Chauhan
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 6.  Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities.

Authors:  Jiri Rehak; Matus Rehak
Journal:  Curr Eye Res       Date:  2008-02       Impact factor: 2.424

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.